Adjuvant Chemotherapy After Radiotherapy in Hodgkin's Disease
Author Information
Author(s): H. Anderson, D.P. Deakin, J. Wagstaff, J.M. Jones, I.D.H. Todd, P.M. Wilkinson, R.D. James, W.P. Steward, G. Blackledge, J.H. Scarffe, D. Crowther
Primary Institution: Christie Hospital, Manchester
Hypothesis
Does adjuvant chemotherapy improve relapse-free survival and overall survival in patients with supradiaphragmatic Hodgkin's disease after mantle radiotherapy?
Conclusion
Adjuvant chemotherapy significantly improved relapse-free survival but did not enhance overall survival in patients with Hodgkin's disease.
Supporting Evidence
- All patients achieved a complete remission.
- Relapse-free survival was 81% overall, with 69% for radiotherapy alone and 93% for adjuvant chemotherapy.
- High-risk groups for relapse included those with bulk disease and B symptoms.
- Overall 5-year survival was 93% with no significant difference between treatment groups.
Takeaway
This study found that giving extra chemotherapy after radiation helps prevent cancer from coming back, but it doesn't help people live longer overall.
Methodology
Patients were randomized to receive either mantle radiotherapy alone or mantle radiotherapy followed by six courses of adjuvant chemotherapy (MVPP).
Potential Biases
Potential bias due to exclusion of patients with massive mediastinal disease and those outside the age range.
Limitations
Some patients did not complete the full course of chemotherapy due to toxicity, which may affect the results.
Participant Demographics
Patients aged 16-65 with newly diagnosed pathologically staged supradiaphragmatic Hodgkin's disease.
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Want to read the original?
Access the complete publication on the publisher's website